Abstract
Fewer than one million HIV infected individuals are currently receiving antiretroviral therapy. Present antiretroviral therapy costs between $10,000 and $20,000 per year, which provides excellent value for money in developed countries with a cost of about $10,000 per life year saved; this compares very favourably with other therapies in chronic use. Recent studies have demonstrated a dramatic decline in HIV and AIDS related morbidity and mortality across developed countries and these reductions have been sustained since the introduction of highly active antiretroviral therapy (HAART) since 1996. The use of HAART has been associated with specific toxicities related to the drug class, problems with adherence with the subsequent emergence of viral isolates and resistance associated mutations. The replacement of older therapies with newer drugs that avoid cross resistance even within the same class of antiretroviral, represents a new hope in retroviral targeting.
Keywords: antiretroviral therapy, proteinase inhibitors, Reverse transcriptase inhibitors, Elvucitabine, Amdoxovir, thymidine-associated mutations, Capravirine
Medicinal Chemistry
Title: The Rationale and Development of New Drugs to Treat HIV Infection
Volume: 1 Issue: 6
Author(s): J. Stebbing, E. Hatzimichael, M. Bower and A. Winston
Affiliation:
Keywords: antiretroviral therapy, proteinase inhibitors, Reverse transcriptase inhibitors, Elvucitabine, Amdoxovir, thymidine-associated mutations, Capravirine
Abstract: Fewer than one million HIV infected individuals are currently receiving antiretroviral therapy. Present antiretroviral therapy costs between $10,000 and $20,000 per year, which provides excellent value for money in developed countries with a cost of about $10,000 per life year saved; this compares very favourably with other therapies in chronic use. Recent studies have demonstrated a dramatic decline in HIV and AIDS related morbidity and mortality across developed countries and these reductions have been sustained since the introduction of highly active antiretroviral therapy (HAART) since 1996. The use of HAART has been associated with specific toxicities related to the drug class, problems with adherence with the subsequent emergence of viral isolates and resistance associated mutations. The replacement of older therapies with newer drugs that avoid cross resistance even within the same class of antiretroviral, represents a new hope in retroviral targeting.
Export Options
About this article
Cite this article as:
Stebbing J., Hatzimichael E., Bower M. and Winston A., The Rationale and Development of New Drugs to Treat HIV Infection, Medicinal Chemistry 2005; 1 (6) . https://dx.doi.org/10.2174/157340605774598199
DOI https://dx.doi.org/10.2174/157340605774598199 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antineoplastic Activity, Structural Modification, Synthesis and Structure-activity Relationship of Dammarane-type Ginsenosides: An Overview
Current Organic Chemistry Angiotensin 1-7 Promotes Cardiac Angiogenesis Following Infarction
Current Vascular Pharmacology Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases
Current Medicinal Chemistry Physiological Changes in the Critically Ill Patient with Sepsis
Current Pharmaceutical Biotechnology Targeting Potassium Channels: New Advances in Cardiovascular Therapy
Recent Patents on Cardiovascular Drug Discovery Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design Pathophysiology of Atherosclerosis: The Role of Inflammation
Current Pharmaceutical Design Anti-Inflammatory Treatments for Chronic Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued) The Role of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke: From Laboratory to Clinics
Current Vascular Pharmacology Free Radicals in Diseases and Potential Role of Phytoconstituents-A Cause with Emerging Importance
Current Chemical Biology GCPII Variants, Paralogs and Orthologs
Current Medicinal Chemistry Thalidomide Metabolism and Hydrolysis: Mechanisms and Implications
Current Drug Metabolism 4’-Aminochalcones As Novel Inhibitors of the Chlorinating Activity of Myeloperoxidase
Current Medicinal Chemistry Glucocorticoids and Vascular Reactivity
Current Vascular Pharmacology The Influence of Different Disease States on Rituximab Pharmacokinetics
Current Drug Metabolism The Use of Statins in Respiratory Diseases
Current Respiratory Medicine Reviews Biologic Therapy in Inflammatory Eye Conditions (Ophtalmology): Safety Profile
Current Drug Safety Management of Vasculopathy in Connective Tissue Disease
Current Rheumatology Reviews The Role of 18FDG PET/CT in the Assessment of Endocarditis, Myocarditis and Pericarditis
Current Radiopharmaceuticals